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A characteristic feature marking the early 
history of curare, is the confusion about its actions 
chiefly resulting from the lack of exact data in the 
correlation of crude curare with definite botanical 
sources. The art of curare -making is rapidly becom- 
ing lost, and has been displaced, at present, by a 
rising tide of enthusiasm for its clinical applicat- 
ions. 
However, one of the most reliable life - saving 
measures in curarization, which still maintains its 
importance in clinical practice, was demonstrated by 
Brodie in 1811, who showed that artificial respiration 
was capable of supporting life in fully curarized ani] 
mals.(20). Brodie's experiments on artificial resp- 
iration were extended by Waterton, and applied to 
larger anßmals.(116). These experiments were import -1 
ant, because they led, in 1814, to the use of curare 
in the treatment of tetanus of horses, from which 
stemmed the clinical use of curare in man.(87). 
It was not until 1856, when the chief action 
of curare on the neuromuscular transmitting 
apparatus/ 
-2- 
apparatus was shown by Claude Bernard, in his experi- 
ments on the muscle -nerve preparation, which are 
classical examples of pharmacological demonstrations 
in their simplicity and final implications.(9,10). 
His first paper on curare appeared in 1850, and was 
written in conjunction with Pelouze.(8). 
In analogy with Claude Bernard findings, 
were those of Kölliker, in 1856(77), and Kt4hne, in 
1860(80); and lately of Steiman, in 1943, on the 
nerve single -muscle fibre preparation.(110). The 
study by Lucas, of the electrical properties of the 
nerve, nerve endings, and muscle, made it also poss- 
ible to determine a differential action of curare on 
the muscle -nerve unit.(84). 
It may be owing to the stimulating effects 
of Claude Bernard researches, that the therapeutics 
of curare were tried in France at an early date, by 
Thiercelin (112); followed by Benedict (4); and later 
by Lionville and Voisin (83); who tried to allay and 
prevent the convulsions of epilepsy in man, but their 
project was interrupted by the lack of a continued 
supply of curare. 
Beigel, in 1868, was the first to employ a 
crystalline/ 
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crystalline curare preparation in man, by using 
Preyerts "Urarin ",(3,99); and his reports are of 
special interest, as he was among the first to des- 
cribe the signs of curarization in man. Hunter, in 
1878,(65); followed by Hoffmann (61); described the 
use of curare for the treatment of tetanus; and in th 
following year Offenberg (92), attempted to use it in 
the treatment of hydrophobia. 
Then the drug fell apparently into disuse 
until 1931, when interest was again stimulated by West, 
who, together with Hartridge, were able to remove the 
muscular spasm of tetany in dogs, without affecting 
their power of locomotion.(59). It was again hoped 
that the lissive action of the drug may be helpful in 
removing the rigidity of tetanus for which condition 
it was tried by Cole, in 1934; by Mitchell, in 1935; 
and by West, in 1936; but the results as a whole were 
not very encouraging.(30,90,118,119). Recently, how- 
ever, Edwin and Laurence in 1948, reported successful 
management in two cases of tetanus by intocostrin, 
where they also noticed that the drug was more effect- 
ive than codeine in relieving the pain of muscular 
spasm. (40) . 
A/ 
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A beneficial effect in some spastic conditi- 
ons was also reported by Burman in 1939,(24); and by 
Schlesinger in 1946 (104), to follow the injection of 
curare preparations. 
Current enthusiasm for the clinical applica- 
tion of curare is also largely due to the efforts of 
Bennett, a psychiatrist in Omaha, who, in 1940, popu- 
larized the use of curare to control the convulsions 
associated with metrazol or electric treatment, in 
which case the drug is described to be "tailor made" 
as a shock- absorber.(5). Subsequent reports by Gray, 
Fechner and , pradling (51); Cummins (37); Cash and 
Holkestra,(25); Stewart,(111); and others, have pro- 
vided ample evidence of the great value of curare in 
convulsive shock -therapy. 
The inception of curare in anaesthesia dates 
back to 1912, when L.wen, the surgeon, used it to 
produce muscle relaxation during surgical operations, 
(82). Then apparently nothing was recorded about the 
use of the drug in this field until 1942, when Griff- 
ith and Johnson of Canada described their experience 
with intocostrin in twenty -five cases on the suggest- 
ion of Dr. Lewis H. Wright155).Then the application o 
the/ 
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the drug as an adjuvant in anaesthesia for the attain - 
ment of profound muscular relaxation, without the use 
of excessively large doses of the anaesthetic, was 
more widely investigated, and in the following year, 
Cullen published careful and clearly detailed observ- 
ations on a large number of cases in the States.(35). 
Other reports describing the usefulness of curare in 
anaesthetic practice include those of Brody, using 
sodium pentothal- nitrous -oxide oxygen anaesthesia.(21) 
Cole, using cyclopropane (31); Harroun, Beckert and 
Hathaway, using nitrous oxide (58); Shane (106); 
Forrester (43); Gray and Halton (52,53); and many 
others, using various anaesthetic agents. All work- 
ers reported the same general findings: good condition 
of patients during operation, expedition of the surg- 
eons' work and low incidence of post -operative com- 
plications. By 1947, there was a world -wide inter- 
est in the clinical use of curare and a bibliography 
recording its effects is rapidly growing. Thus the 
death drug of the blowpipes has become a powerful 
weapon in the treatment of spastic conditions and a 
great addition to the art of anaesthesia. 
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CIEIISTRY 
As was mentioned before, curare is not a pure 
substance, and the need for isolating a purified act- 
ive principle from crude curare started as early as 
1828, in South America, when Boussingault and Roulin 
succeeded in obtaining a bitter principle which they 
Ì 
differentiated from strychnine isolated eight years 
previously by Pelletier and Caventou.(1'7). But app- 
arently "curarine or "urarine" was the first alkaloi 
isolated in a crystalline form by Preyer, in 1865(99). 
The chemical problem was somewhat clarified 
by the work of Boehm, who found that in general, the 
containers were fairly diagnostic of the curare in 
them and he accordingly divided curare into three 
types: calabash curare; pot curare, and tube curare. 
They all contained active quaternary alkaloidal frac- 
tion which he called "curarine"; the pot and tube 
curares contained, in addition, tertiary alkaloids, 
which are less active and which he termed "curines''. 
(14,15). Unfortunately, Boehm's curarme, which was 
not obtained by him in a crystalline form, thus being 
not a pure substance, has been utilized in much of 




For many years, it was thought that the 
curare exported in the three types of containers, had 
been obtained and prepared from different types of 
plants, until Gill, in 1946, discounted this idea 
showing that regardless of the plants from which a 
given batch of curare had been prepared, the batch was 
simply placed in the most accessible container.(48,49). 
It was Harold King, in 1935,(73), who was the 
first to obtain and work out the formula of the active 
crystalline alkaloidal salt: dextro - tubocurarine chlo- 
ride, isolated from a specimen of 25g. of native tube 
curare provided by the museum of the Pharmaceutical 
Society. In subsequent publications, King directed 
the attention to members of the family "Menispermaceae" 
especially the genus "Chondrodendron" as likely 
sources of the drug.(74,75). 
Another major contribution to the chemistry 
of curare was made by Pistor and Wieland in 1941,(94) 
and by Konz and Wieland in 1943,(78) who were able to 
obtain "toxiferine ", the active principle of calabash 
curare, in a purified form. In 1943, Wintersteiner 
and Dutcher announced the isolation of dextro-tubo- 
curarine chloride in a good yield from curare obtain- 




Structural formula of d- tubocurarine 
chloride, isolated in 1943 from chon- 




tosum. Thus they obtained the alkaloid for the first 
time, from a single plant species, which is probably, 
by far, its chief botanical source. The structural 
/formula of this alkaloidal salt is shown in Fig.I. 
They also extracted two new tertiary alkaloids which 
could be converted into physiologically active quat- 
ernary bases and noticed that methylation of the 
phenolic- hydroxy group of the latter compounds resul- 
ted in a 3 -9 fold increase in their physiological 
activity.(122). 
In 1939 -1940, a new reliable and stable pre- 
paration of curare "intocostrin ", marketed by "Squibbl! 
was introduced in the U.S.A. as a result of the work 
of Gill,(47) and others. It is a purified stand- 
ardized extract of crude curare containing a mixture 
of alkaloids of which tubocurarine is the most import- 
ant and of which one unit equals the specific activity 
(contained in lmg. standard crude curare, and this is 
equivalent to 0.15mg. tubocurarine, by the head -drop 
method.(34,85). Clinically, however, this ratio 
is probably in the region of 2.5 -3 units intocostrin 
to each lmg. tubocurarine.(95,98). 
Thus the isolation of an active alkaloid, 
with clinical importance, from curare would make a 
systematic study more feasible. Nevertheless, the 
fate/ 
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fate of the drug in the body has, probably, received 
less attention than any other aspect of its pharma- 
cology, and the present work is an attempt towards 
providing some information about this point. 
study of the fate of tubocurarine in the 
body would necessitate two main requirements: - 
I. A suitable method of assay which should be 
sensitive enough to detect minute amounts of the drug. 
likely to be encountered. 
II. A suitable method for extracting the drug 
from the various tissues and biological fluids, and 
the presentation of the final extract in a form suit- 
able for the test. 
-10- 
PART I 
METHODS OF A $ 3A CF CURARE PREPARATIONS. 
The methods of assaying curare in general are 
either chemical or biological. 
Chemical methods: 
1 In 1903, Barbosa published elaborate 
colour charts depicting the colours obtained with vari- 
us curare compounds.(2). Qualitative, though non- 
specific, reactions for the curare alkaloids with 
otassium ferrocyanide, were described by Cole, in 
923 (29); and with trichloracetic acid by Schoofs in 
927 (105) . 
Recently, Foster and Turner (1947), have de- 
veloped a tentative polarimetric method for the assay 
of dextro- tubocurarine chloride. They also described 
colorimetric method for the assay of the alkaloid 
epending on the use of Folin -Ciocalteu phenol reagent. 
(44). 
411 these methods, however, must be of 
limited application on account of the many materials 
which yield a colour with the reagent, and the high 
concentration required to be detectable. 
Furthermore, the physical and chemical data 
about/ 
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about dextro- tubocurarine chloride are not sufficient- 
ly well defined to exclude contamination with active 
compounds and therefore the biological tests remain 
essential for evaluating its activity.(70). 
Biological methods: 
These depend either on the use of 
the whole animal or the isolated muscle preparation. 
Whole animal: 
(1) One of the early methods was used by 
Gaddum in 1937, and consisted in determining the 
quantity of the poison which would prevent the frog's 
body -righting reflexes from functioning for one min- 
ute within fifteen minutes of the injection as shown 
by the inability of the animal, when laid on its 
back, to recover its normal posture within one min- 
ute. The minimum quantity producing such an effect 
was defined as the paralysing dose. Injections were 
made into the ventral lymph sac of the frog, and con - 
tained in a volume of solution corresponding to 
0.02c.c. /g. body weight.(45). 
(2) In 1941, the "Head- drop" method was 
developed by Holaday, which employs muscular relaxa- 




To reach a head -drop dose, a rabbit is tied, 
belly downwards, and given an interrupted intravenous 
injection of a solution containing two units into - 
costrin /ml, at a rate of 0.1m1. every fifteen seconds, 
until the muscles supporting the head become suffici- 
ently relaxed to prevent its being raised when the 
back is stroked.(6). In this respect, it may be 
noted that the head -drop dose in different rabbits, 
even of the same weight and sex, varies widely, and 
therefore it is Important to compare the potency of 
the unknown with that of the standard on the same 
animal, the assay being applied as a two days cross- 
over test and the average head -drop dose per kg. body 
weight (H.D.50) determined.(63). 
(3) The intravenous injection of curare in 
mice, likewise produces a head- drop.(72). This 
method, described by Kimura and Unna in 1948, is 
claimed to be more economical and allows the statis- 
tically valid determination of the head -drop dose on 
a uniform population. 
In this connection, however, it may be noted 
that the difference between the H.D.50 and the L.D.50, 
represents the margin of safety of the drug, and that 
this margin is so narrow, that the determination of 
the/ 
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the H.D.50, often results in loss of the animal. 
Moreover, in a head -drop method, the results 
are not recorded objectively. 
(4) Skinner and Young described in 1947, a 
"mouse- method" of assay for curare activity, as being 
simple and objective.(108). In this method young 
female mice are used, twenty -five of them are assign- 
ed, at random, to each of four dose levels, arranged 
in geometric progression. Then, immediately after 
the subcutaneous injection of the dose, in a suitable 
volume of fluid, the mice are placed in rotating 
cylinders, and the mice falling away from the cylin- 
' ders during the first twenty minutes are considered 
reactors. 
Then the proportion of mice reacting at the 
different dose levels are transformed into probits, 
and the slope of the logarithmic dosage response rel- 
ationship computed in the usual manner. 
(3) In 1948, Marsh and Pelletier, used a 
method of assay depending on comparing the paralytic 
doses for rats, i.e., finding the dose producing 
paralysis of the hind limbs for a minimum of three 
minutes in a group of twenty rats.(89). 
The main use of any of these methods, at 
present, is mostly confined to the evaluation of 
compounds/ 
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compounds with curare -like activity. 
Even there, they all suffer from the disad- 
vantage that they do not establish the site of action 
of the drug, which is one of its most characteristic 
features. 
Isolated muscle p paration: 
1. The frog's nerve -muscle preparation: - 
Here the gastrocnemius- sciatic, or the 
nerve - sartorius preparation of the frog (Rana tempo - 
raria), has been used. 
Ing and Wright (67), found that the nerve - 
sartorius preparation was the more suitable, as the 
muscle is thinner and the time of diffusion of the 
drug is almost negligible. 
In these cases, most authors (for reference, 
see Ing,1936(68), have estimated either concentrat- 
ions of curare which paralysed the muscle completely, 
or concentrations which just failed to cause complete 
paralysis. After such severe poisoning, recovery is 
usually slow. 
2. The rat's phrenic nerve diaphragm prep- 
aration:- 
In 1930, Dale and Gaddum described experi- 
ments on the denervated kitten's diaphragm in their 
investigations/ 
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investigations on the reactions of denervated volunt- 
ary muscle.(38). 
Bttlbring in 1946, tried to use the same pre- 
paration with the phrenic nerve attached, in investi- 
gating the effects of certain autonomic drugs on 
neuromuscular transmission. The thinner muscle of 
the rat's diaphragm, however, was found more suitable 
for this purpose.(23). 
This preparation was subsequently used by 
Chou in 1947, in working out a method for the esti- 
mation of curare -like activity.(27). Jalon and West 
in 1947, found that, in this preparation, if the 
temperature of the bath was kept at a lower level than 
that used for mammalian tissue work, namely at room 
temperature, results were more cor,stant.(71). West 
in 1948, also noticed that under these conditions, 
the addition of small quantities of potassium ion to 
the bath, enhanced recovery.(117). It may be 
noticed, however, that the use of this method for 
assay would require the presence of the test subst- 
ance in relatively large amounts. 
3. The frog's rectus- abdominus muscle 
method: - 
The action of acetylcholine on the frog's 
rectus/ 
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rectus abdominus muscle was first described in 1921, 
by Riesser.(100). The use of this preparation in 
the biological assay of acetylcholine, and in the 
measurement of the acetylcholine- equivalent of tissue 
extracts provides one of the most sensitive methods 
for the purpose.(26). The present method depends on 
a measurement of the antagonism between acetylcholine 
and tubocurarine, and although it is probably more 
sensitive than other methods, it is not specific. 
antagonism between cholinergie drugs and curare was 
first reported by Pal in 1900.(93); and further in- 
vestigated by Rothberger,(101); by Magnus,(88); by 
Ikeda,(66); and many others. Hori in 1927, attempt- 
ed to place the eserine- curare antagonism on quanti- 
tative bases.(64). 
Jacobsohn and Kahison also demonstrated, in 
1938, the anticurare effects of various substances 
with anticholinesterase activity.(69). In 1944, 
Koppanyi and Vivino (79), in their work on the decur- 
arizing effects of the anticholinesterases showed 
that small doses of physostigmine would prevent par- 
alysis and death in rabbits after a usually lethal 
dose of dextro- tubocurarine chloride. 
The acetylcholine and related curare antag- 
onists/ 
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onists were also extensively investigated by Briscoe, 
who showed that such an antagonirn is most probably 
due to a riso in the threshold of response to the 
transmitter.(18,19). Furthermore, it has been shown 
by Brown, Dale and Feldberg (1936), that curarine re- 
duces the ability of intra- arterial injections of 
acetylcholine to cause contraction in normal muscle. 
(22). 
However, one of the most important facts that 
came to be known about curare in the present time, is 
due to the work of Dale, Feldberg and Vogt, in 1936, 
who showed that when transmission of excitation from 
the nerve to the perfused muscle is prevented by cur - 
arine, stimulation of the motor nerve still caused 
the usual release of acetylcholine.(39). 
Hence, there is a considerable body of evi- 
dence that the curarine- acetylcholine antagonism is 
brought about by curarme causing a rise in the thres- 
hold of response of voluntary muscles to acetylcholi 
This rise in the threshold- response has been found by 
Jalon to be directly related to the dose of tubocura- 
rine used. This was the basis of a method, develop- 
ed in 1947, for the biological assay of curare prepa- 
rations, using the frog's rectus abdominus muscle.(70). 
This method was adopted as it was found more suitable 
for / 
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for the purpose of the present work. 
The bath used here for this preparation con- 
tains 2c.c. Ringer's solution at room temperature, 
aerated by a continuous stream of oxygen bubbles and 
the contractions are recorded on a slowly moving 
smoked drum. The magnification is about ten and the 
tension about 3g. weight. 
4 suitable fixed dose of acetylcholine is 
added to the bath every six minutes, and allowed to 
act for exactly two minutes before it is changed, and 
the preparation washed and allowed to relax. When the 
responses of the rectus muscle to acetylcholine have 
become quite regular, a suitable volume of the solu- 
tion to be tested is added ninety seconds before the 
addition of acetylcholine, and its effect on subse- 
quent responses to the latter observed. 
When doses are thus added at a constant time 
interval, the effect produced in the given constant 
time is regularly related to the dose and can be 
taken as an index of the potency of the solution. 
Thus a quantitative estimate of the curariform activ- 
ity of an extract is obtained by comparing it with a 
solution of tubocurarine, given in alternate doses. 
By this procedure it was possible to detect 
activities corresponding to 0.1µg. tubocurarine. A.s 
it/ 
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it made no difference to the assay whether or not 
the rectus had been sensitized beforehand by eserine, 
so the uneserinized preparation was preferred. 
-20- 
THE PREPARATION OF EXTRACTS 
Tubocurarine is soluble in alcohol and is not 
inactivated by desiccation or by alkali.(34). In ex- 
tracting added or injected tubocurarine from the vari- 
ous tissues and biological fluids, the following meth- 
ods were tried. 
Extraction from the blood: 
In preliminary experiments on whole blood in vi- 
tro, most of the drug added, was recovered from the 
plasma, by the use of acid alcohol and none from the 
blood cells. After injection, extraction of the 
drug was tried in the following way: 
The blood was drawn on heparin over ice and 
the plasma immediately separated. The acid alcohol - 
prepared by acidifying absolute ethyl alcohol with a 
crystal of tartaric acid or with 0.lc.c. normal hydro- 
chloric acid - is used in a dose of 10 -15m1, acidified 
alcohol for each lml. plasma. 
The plasma was then added to the acidified 
alcohol dropwise, shaking thoroughly after each addi- 
tion. The precipitate was separated and washed with 
acid alcohol and the alcoholic solution taken down to 
dryness, and the residue dissolved in Ringer's solut- 
ion/ 
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ion and filtered. 
Extraction from the urine: 
4 certain volume of the urine was evaporated to 
dryness on the water bath. The solid residue was then 
thoroughly mixed with absolute ethyl alcohol, 5ml. for 
each 1ml. urine, and the precipitate separated by 
centrifuge and washed with same absolute alcohol. 
The alcoholic solution was then evaporated 
to dryness, and the final residue taken up in Ringer's 
solution, 1 -10m1. for each 10m1. urine; thus the 
tubocurarine in the urine could be concentrated 1 -10 
times. 
Extraction from the tissue: 
In extracting the drug from the tissues, several 
methods were tried. A. convenient one was found to de- 
pend on extraction with acid -alcohol, and here the 
use of sulphuric acid as an acidifying agent was 
found, in most cases, superior to hydrochloric acid 
in providing a final clear extract. This was observed 
by Chang and Gaddum in 1933, when they were estimating 
the acetylcholine equivalent of tissue- extracts.(26). 
This method extracted the acetylcholine equivalent of 
the tissues, along with their tubocurarine content, 
and acetylcholine was present in such quantities as 
to interfere with the test and mask the curariform 
activity/ 
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activity of the extract; but it was finally removed 
from the extract by hydrolysis. 
It may also be noticed that extracts prepa- 
red in this way may contain other pharmacologically 
active substances, and are only therefore suitable 
for use in a biological test when the physiological 
reaction used in this test is one which is relatively 
little affected by these substances. This is anoth- 
er advantage of the frog's rectus abdominus muscle in 
this respect, since such substances are without appar- 
ent effects on this preparation.(26). 
Extraction of the drug from the tissues was 
then tried in the following way: 
The tissue was weighed, cut up with scissors and 
mixed with acidified alcohol,(15- 20c.c. per g.tissue) 
where its cutting up and mixing was completed. This 
acidified alcohol was prepared by adding 1.2ml. 2N. 
H2304 to each 100m1, of absolute ethyl alcohol. The 
deposit was then separated by centrifuge and washed 
with acid alcohol, and the alcoholic solutions evapo- 
rated to dryness and taken up in Ringer's solution 
and filtered. The extract was then made slightly 
alkaline (pH 8.3) and boiled for one to two minutes 
to destroy its acetylcholine, but not tubocurarine. 
It was neutralised and concentrated until lc.c. corre- 
sponded/ 
-23- 
sponded to 1 -5g. tissue. 
Extraction from other biolo icai s<aterial,s: 
Faeces: In some ani al experiments, it was 
desired to look for the presence of the drug in the 
faeces. Here the masses were powdered and a weighed 
quantity transferred to a dry clean mortar and abso- 
lute ethyl alcohol - 10ml. per g. - added to the con- 
tents of the mortar and mixed thoroughly. Then the 
deposit was separated and washed with alcohol, and 
the alcoholic solutions finally taken down to dryness 
and the residue dissolved in Ringer's solution and 
filtered. 
Gastric iuice: In the conscious human subject, 
excretion of the drug was sought for in the saliva 
and gastric juice. The fasting gastric juice aspir- 
ated through a Ryle *a tube was well shaken and filter- 
ed. The filtrate was heated on the flame and the 
eoagulum separated. Then the clear fluid neutral- 
ised and used for the test. 
Saliva: This was collected after the mouth had 
been thoroughly cleaned and rinsed. To each 9ml. 
absolute alcohol, acidified by a few drops of dilute 
HCl, lc.c. saliva was added, drop by drop, shaking 
thoroughly after each addition and for sufficient 
time/ 
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time at the end. The thin precipitate was separated 
and washed with acid alcohol. The alcoholic solut- 
ions were evaporated to dryness and the residue taken 
up in Ringer's solution and filtered. 
It may also be mentioned that, in the case 
of biological fluids, a control sample of the fluid 
was always obtained before the injection of the drug 
was made and was extracted and examined in the same 
way as the post injection samples. 
When the samples, obtained after the inject- 
ion, showed measurable curariform activities, this 
usually decreased as the time interval after which 
the sample had been obtained, became longer until it 
faded away approaching the blank control. Such an 
activity was assumed to be most probably due to the 
presence of the drug - in same form - in the corres- 
ponding fluid. As for the tissues, a control extract 
was prepared from the corresponding tissue of a con- 
trol animal, chosen preferably of the same sex, and 
as near as possible, of the same weight. The con- 
trol biological fluids and tissue extracts thus ob- 
tained were devoid of curariform activity. All extr- 
acts were, if necessary, made neutral before they 
were used in the test. 
-25- 
RESULTS 
In order to test the accuracy of the methods 
used, the recovery of known amounts of dextro- tubocu- 
rapine chloride added to the various tissues and bio- 
logical fluids, was tried. The drug is often referred 
to here as "tubocurarine" or abbreviated as "d.T.0 ". 
Table I, shows that the recoveries of known amounts 
added to blood, urine and saliva, were satisfactory. 
Table I 







Human 2.0 1.80 +10 
blood 1.0 0.90 +10 
1.0 1.0 00 
Rabbit's 2.0 1.9 +5 
blood 1.0 0.85 +15 
1.0 1.12 -12 
Mean +4 .6 
Human 2.0 1.9 +5 
urine 1.0 1.0 00 
Rabbit's 2.0 1.90 +5 
urine 1.0 1.15 -15 
Rat's 1.0 1.0 00 
urine 1.0 0.90 +10 . 
Mean +0.83 
Human 2.0 2.10 -5 
saliva 1.0 0.85 +15 
1.0 0.85 +15 
Mean +8.3 
-26- 
In Table II, the recoveries of known amounts 
added to the various tissues are represented. 
Table II 







Minced 1.0 1.10 -10 
mouse 1.0 1.05 -5 
0.5 0.45 +10 
Rabbit's 1.0 1.07 -7 
liver 1.0 0.9 +10 
Rabbit's 0.5 0.45 +10 
muscle 0.5 0.4 +20 
Rabbit's 0.5 0.45 +10 
kidney 0.4 0.35 +12.5 
Mean +5.. 
Blood levels and volumes of distribution of 
tubocurarine in man. 
In these experiments, samples were obtained 
from anaesthetized patients undergoing surgical oper- 
ations, and from the conscious unanaesthetized subject. 
In the first case, the patient of choice was. 
one/ 
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Blood levels and volumes of distribution of 
tubocurarine in man. 
In these experiments, samples were obtained 
from anaesthetized patients undergoing surgical oper- 
ations, and from the conscious unanaesthetized subjec 
In the first case, the patient of choice was, 
one/ 
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one undergoing a surgical operation of a relatively 
short duration, thus requiring not more than a single 
dose of the drug. Intravenous anaesthesia was avoid- 
ed, and the patients were kept under cyclopropane- 
oxygen anaesthesia. 
9 study of the fate of the drug in man was 
made by determining the blood levels of the drug at 
various intervals following its intravenous adminis- 
tration; by determining the amount excreted in the 
urine and, in the conscious subject, by detecting and 
estimating the drug in some other accessible biologi- 
cal fluids: i.e., the saliva, gastric juice and cere- 
bro- spinal fluid. 
Experiments on patients: 
In the surgical cases, control samples of blood 
and urine were always drawn, on the operation table, 
during the second plane of anaesthesia, and just 
before the administration of tubocurarine. Then the 
drug: "Tubarine, "B.W "., 0.2mg. /kg. was injected intra- 
venously. 
Blood samples were drawn on the third, fif- 
teenth and thirtieth minute following the injection. 
Whole urine specimens were collected at hourly inter- 
vals after the injection, the pre -injection and first 
post/ 
-28- 
post injection samples were usually drawn by a sterile 
rubber catheter. All samples were extracted and 
examined for their curariform activity and the concen- 
trations of the drug estimated. 
The various blood concentrations and volumes 
of distribution of the drug in the human subjects, 
(4 anaesthetized patients:A,B,C,D; and 1 conscious 
subject :E) at the specified intervals are given in 
Table III. 
TABLE III 
The blood concentrations and volumes of distributign 
of tubocurarine in human subjects, following the intra- 




µg. /ml. of plasma. 
3 min. 15 min. 30 min. 
Appendi- 
cectomy 4.2 2.6 0.8 
B Ulnar ner- 
ve suture 3.5 2.8 1.0 
C Laparot- 
omy 4.6 2.4 1.2 
D Laparot- 
omy 3.2 2.2 0.9 
E (Conscious) 4.5 3.0 1.1 
Mean concentration 4.0 2.6 1.0 
concentration 1.30 L 1.114 
0.70 
o .mean 
'°6 *Dose (mg./kg.) 
Volume of distri- 
bution,4/100kg . 5 7.7 20. 
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The relation between the dose of the drug 
and its average concentrations in the blood, at vari- 
ous times following the intravenous administration is 
shown in Fig.II. 
The ordinate corresponding to zero time is 
1.38 or log.24. The volume of immediate distribution 
is thus estimated as 100/24 or 4.2 which is probably 
about equal to the plasma volume. This may also show 
that the drug probably does not pass into the blood 
corpuscles. 
Experiments on the conscious subject: 
Experiments were conducted on a 75kg. healthy 
medical man (self), not undergoing operation and with 
no concurrent pathological history with the object of: 
1. Observing the onset and nature of the clinical 
symptoms of curarization in man. 
2. Attempting to correlate this clinical symptomat- 
ology with the blood levels of the drug and its 
urinary excretion. 
Two experiments were performed: 
Experiment I: 
Here the drug: Tubarine, "B. W. " 
was injected in a small single dose, 7.5mg. slowly 
intravenously over a period of two minutes. Within 
one minute from the beginning of the injection, i.e., 
after; 
-30- 
after about 3,5 mg. were injected. There were defin- 
ite myasthenic symptoms and descending paralysis invo- 
lving the eyelids, face, neck muscles and the extrem- 
ities. The movements of the eyes became sluggish and 
the gaze tended to be fixed. There was also some 
heaviness of the tongue, with difficulty of speech and 
harshness of voice. iUthough these symptoms were in- 
creasing in severity, and towards the end of the inje- 
ction were actually alarming, no respiratory difficul- 
ty was complained of. In this connection it may be 
noted that Gray and Walton, in 1948 (54), noticed the 
development of such severe symptoms in a non myasthe- 
nic case following the injection of a small dose, 2mg. 
of tubocurarine. Thus it appears that the occurrence 
of alarming myasthenic symptoms following the injectiop 
of small doses of the drug, is not necessarily a spec- 
ific reaction of the myasthenic, and that the advo- 
cated use of small doses of the drug as a specific dia- 
gnostic test for myasthenia gravis (7), should be reg- 
arded with caution. 
Experiment II: 
On a later occasion, the drug 
(15mg. Tubarine, "B.W" .) was injected into the same 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































A means of communication had been established 
beforehand between the subject and the operators, 
since paralysis of the tongue muscles was almost cer- 
tainly expected. 
For a period of not less than half a minute 
after the injection, muscular power was almost full 
and no symptoms were at all experienced, then the sub- 
ject was suddenly caught by a severe asthmatic attack. 
At this stage, muscular power was apparently 
still_ full, because the subject was able to move his 
arm pointing with his palm to the face, asking for the 
oxygen mask. The mask was put on, and artificial re- 
spiration conducted with oxygen under positive pressure. 
Despite this artificial aid to the respiration, 
the respiratory embarrassment maintained its severity 
for about three minutes during which the subject was 
thrown into occasional convulsions, probably anoxa.emic. 
The condition, however, was not painful but was most 
distressing (see the anaesthetist report: Remark IV, 
Table IV: subject very distressed and convulsing). 
Shortly afterwards, he was lying flaccid with . 
full ptosis, and muscular paralysis. The tongue did 
not fall to the back of the throat and the upper air- 
ways were not plugged with mucous. 
Consciousness/ 
-33- 
Consciousness was not lost, and the memory 
was not clouded. 
The colour of the skin was normal or slightly 
pinkish, and there were no evident changes in the sen- 
ations. There was profuse sweating of the brow. 
The pulse was accelerated and the blood pres- 
sure slightly raised during the fifteen minutes follo- 
wing the injection, then gradually came down to the 
original level. 
The subject was starved for seventeen hours 
before the experiment; and all the control samples 
were collected before the administration of the drug. 
Following the injection, blood samples were drawn on 
the third, fifteenth, and thirtieth minute. 
The saliva sample was collected on the twenty- 
first minute. 
The spinal canal was tapped and a sample of 
cerebro- spinal -fluid drawn thirty -three minutes after 
the injection; and ten minutes later, a specimen of 
the fasting gastric juice was aspirated. 
Result of assay: 
The drug was detected in the saliva in 
a concentration of 1.2p.g. per ml. 
Thirty -three minutes after the injection, the 
concentration/ 
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'concentration of the drug in the C.S.F. was 2.511g./m1. 
About 12% of the injected dose was recovered 
from the gastric juice. This amount is probably going 
to the waste, as it was shown, in later experiments, 
that about 25mg. /kg. given by stomach tube to rats is 
generally ineffective. 
In Fig.III, the average levels of the drug in 
the blood of anaesthetized and conscious human subjec , 
following the intravenous administration of 0.2mg. /kg. 
are presented. 
From this curve, it may be noticed that: 
1. A concentration of about 4µg. per ml. of plasma, 
occurring three minutes after the intravenous in- 
jection, seems desirable for the production of 
full muscular paralysis, providing adequate relax- 
ation for surgical procedure. 
This corresponds in the conscious subject to 
the complete classical picture of curarization. 
2. Fifteen minutes after the injection, when the mus- 
cles begin to regain their tone, and in the consc- 
ious subject their power as evidenced by the imp- 
rovement of ptosis and the ability to move a limb 
slightly and use the tongue, the corresponding 
concentration is about 2.6µg. per ml. plasma. 
3 . Half/ 
-35- 
3. Half an hour after the injection, where there was 
apparent recovery, the conscious subject being 
able to sit up and talk - though still feeling 
weak - a level of about 1.0µg. per ml. plasma 
was reached. 
It may be interesting to note that at this 
stage, or even one hour after the injection, where th 
freedom from the symptoms was almost complete, the 
drug was still being excreted and continued to be 
excreted in the urine during the following three 
hours. 
The renal excretion of intravenously admini- 
stered tubocurarine in man. 
The tubocurarine -equivalents of human urine 
following the intravenous injection of the drug, 
(0.2mg. /kg.) in five subjects are shown in Table V. 
TABLE V/ 
-36- 
The renal excretion of intravenous tubocur- 






















4 14 2.82 1.24 0.50 - 4.56 32.6 
B 15 2.48 1.82 0.72 0.3 5.32 35.5 
C 12 2.20 1.24 0.62 - 4.06 33.8 
D 15 2.6 2.02 1.50 - 6.12 40.8 
E 15 3.0 1.4 1.0 - 5.4 36.0 
From the examination of the human urinary 
findings, it may be seen that: 
1. The renal excretion of the drug is relatively 
"slow". It could be detected three hours and 
sometimes four hours after its intravenous admini- 
stration. 
This might explain the common observation of 
the anaesthetist, that if he has to give a second 
dose of tubocurarine during a lengthy operation, 
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full effect; some of the previous dose is prob- 
ably still in the system. 
In the conscious subject, the symptoms of 
curarization practically disappeared about two 
hours before the renal excretion of the drug was 
over. 
The total amount excreted by the kidneys varied 
between 340-4(4 of the intravenous dose given. 
Fig.IV is a graphic representation showing 
the renal excretion of the intravenously admini- 
stered tubocurarine in the normal conscious sub- 
ject. 
-38- 
Urine- histamine followin the intravenous 
injection of tubocurarine. 
The purpose of the following experiment, done 
on an asthmatic patient, was: 
1. To find out whether the histamine, known to be 
liberated as a result of the intravenous inject- 
ion of tubocurarine (56,81), would precipitate 
an attack of asthma in a sensitive individual. 
2. To test if there would be any increase in the 
histamine content of the urine, following upon 
such an injection. 
The patient, a male of 45 years old, has been 
suffering from asthma since 1942. His attacks are 
readily removed by adrenaline. 
Here, the drug: Tubarine "B.W ". was injected 
very slowly intravenously, 10mg. given over a period 
of three minutes. Although there was definite 
ptosis, difficulty of speech with sweating and flush- 
ing of the cheeks, no subjective attack of asthma was 
complained of. 
Result of assays: 
Urine -/ 
-39- 
Result of assays: 
Urine- tubocurarine: Total excretion was 
equivalent to 40% of the 
dose given. 
Urine -histamine: No increase in the hist- 
amine content of the urine 
was detectable in the 
first three hourly speci- 
mens, or in the twenty - 
four hours pooled sample. 
_40_ 
The fate of tubocurarine in the rabbit. 
The fate of tubocurarine in the rabbit was 
studied by determining the blood concentrations at 
various intervals after the injection. The renal 
excretion of the drug was also estimated, and the 
distribution of the drug between the various organs 
examined. 
Blood levels: 
The drug was administered intravenous- 
ly in a single dose of C.12mg. /kg. body weight. A 
control blood sample was usually collected before the 
injection. On the second, tenth and fifteenth min- 
utes after the injection samples were collected, as 
usual, in heparin over ice, the plasma separated and 
extracted, and its activity estimated. Six rabbits 
of both sexes were used. Fig.V represents the aver- 
age concentrations of the drug in the rabbits' blood 
following such an injection. 
From this curve, it may be noticed that: 
1. Two minutes after the injection, and while the 
animal was usually still in a head -drop position, 
the corresponding blood level was about 2.2pg. 
per/ 
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per ml. of plasma. 
2. Ten minutes after the injection, when there was 
apparent recovery, the concentration of the drug 
in the blood was about 1.5µg. per ml. of plasma. 
3. Fifteen minutes after the injection, the corres- 
ponding blood level was about lµg. per ml. of 
plasma. 
In Table VI, the blood concentrations and 
volumes of distribution, at the stated intervals 
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The blood concentrations and volumes of 
distribution of tubocurarine in rabbits following 
the intravenous injection of 0.12mg. /kg. 
Rabbit 
Tubocurarine concentration 
vg./ml. of plasma. 
No. Weight 
Kg. 2 min. 10 min. 15 min. 
1 2 2.1 1.2 0.8 
2 2.4 2.0 1.7 1.2 
3 2. 2.3 1.5 1.0 
4 2.5 2.4 1.7 1.1 
5 2.8 2.2 1.4 1.0 
6 2.8 2.2 1.5 0.9 
Mean concentration 2.2 1.5 1.0 
omean concentration 1.262 1.097 0.92 
Dose (mg./kg.) 
Volume of distri- 
bution. £/100kg. 5.4 8.0 12.0 
Fig.VI, represents the relationship between 





lasma g. k . 
following the intravenous administration of the drug. 
It/ 
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It may also be noticed that, as in the case 
of man, the volume of distribution - theoretically 
calculated from the curve at zero time - corresponds 
approximately to the normal volume of plasma. 
(1.33 =log. 21.4, and 
2104 = 4.7). The drug dis- 
appears from the plasma exporentially, with a halving 
time of about thirteen minutes. 
Renal excretion: 
The urine samples were usually 
collected by a sterile rubber catheter, at the end 
of the second, fourth and seventh hour following the 
intravenous administration of the drug in a dose of 
0.12 mg. /kg. body weight. 
All samples were extracted and examined for 
their curariform activity. It was noticed that samp- 
les, collected at the end of the seventh hour, as well 
as the control samples, were devoid of such an activ- 
ity. 
It was also noticed that the amount excreted 
was usually greatest in the specimen from the first 
two hours and that the total amount excreted by the 
kidneys was between 29 % -39% of the dose administered. 
In Table VII, the tubocurarine equivalents 
of/ 
-44- 
of rabbits' urine, following the intravenous admini- 





















































































































































































































































































































































































































































































































































The distribution of injected tubocurarine in rabbits' 
tissues: - 
The distribution of the drug in the rabbit's 
tissues was examined in two rabbits of different sex 
and of equal body weight. 
Ten minutes following the intraTenaus 
stration of 0.17mg. per kg. body weight, the animals 
were killed by stunning and bleeding and their organs 
removed and extracted by the method meammtio ed previ- 
ously. 
Extracts of brain, kidney z, If-Ter ___ volunt- 
ary muscles were examined for the ,L arif activi- 
ties and the results are shown in fable VIII. 
TABLE VIII. 
The tubocurarine- equivalent of rte'_ _ s" tissue extr- 
acts ten minutes following t'ie is t: - mou administra- 







equivalent 0.16 0.12 1.5 0.10 I 
(vg./g.) 0.15 0.15 2.5 0.13 119 6 
Total 
equivalent 























Average . of 
dose in organ 41.03 0.41 8.91 3.08 
It was noticed that the distribution of the 
drug/ 
-47- 
drug in the organs seemed to be uniform except for the 
kidneys. These showed the highest concentration of 
the drug -equivalent, per gramme tissue. In one case 
this was 1.611g. per g., and in the other 2.5µg. /g. 
The average total tubocurarine- equivalent of 
the kidneys was about 8.9 of the dose given. 
In one rabbit (I), the muscle extract was 
prepared from a specimen of voluntary muscles taken 
from the neck muscles; and in the other rabbit (II) 
it was prepared from a specimen taken from the thigh 
muscles. No appreciable difference, between the con- 
centrations of the drug in the two extracts, was 
noticed. 
The calculation of the total tubocurarine- 
equivalent of voluntary muscles was made on the assum- 
ption that they constitute 45% of the total body 
weight. The high percentage of the dose -equivalent 
present in the voluntary muscles, about 41 %, is there- 
fore largely due to the total weight of the whole 
muscular system. It is possible however, that the 
amounts present in the organs are less than the 
amounts shown, due to the inevitable presence of 
plasma in these organs. 
Similar extracts of the same organs of the 
control/ 
-48- 
control, non injected animal did not show any curari- 
form activity. 
-49- 
The absorption and fate of ingested 
tubocurarine in the rat. 
It has long been believed that curare taken 
by mouth is innocuous, either because it is not absor- 
bed from the gastro intestinal tract, or because it is 
destroyed there, or because it is excreted as quickly 
as it is absorbed, so that an effective blood level is 
not easily reached. 
However, as far as tubocurarine is concerned, 
it was found that: 
1. In the rat, the administration of a dose of less 
than 30mg. per kg. body weight, is usually without 
any apparent effects on the animal, and the pres- 
ence of the drug in the urine or faeces of such 
animals could not be demonstrated. 
2. The ingestion of 30 -40 mg. per kg. body weight re- 
sulted in obvious paralytic signs of variable sev- 
erity. 
While the faeces of such animals were free from 
the drug, the urine (24hours) contained only about 
0.1 -0.2% of the dose given. 
3. The administration of a dose over 40mg. per kg. 
body/ 
-50- 
body weight, resulted invariably in a typical 
picture of curare paralysis of progressive sev- 
erity, ending in death. 
The drug in these cases was administered by 
a stomach tube, after the animal had been starved over 
a night. Animals of both sexes, weighing between 
200 -280g. were used and the results are in Table IX. 
TA,BIE IX . 
The fate of tubocurarine given by stomach 
tube to rats. 
Dose 
mg. /kg. No. of rats Effects Urine Faeces 
10 5 None seen. Nil Nil 
25 5 n if t If 
30 2 variable 
paralysis. 
0.15 ¡o Nil 
35 5 " n 0.1j) n 
40 3 severe par- 
alysis. 
0.2'/,, 




45 3 " 
,? 
- 
From these experiments, it became clear that 
the/ 
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the drug is not innocuous when given by mouth, and 
that absorption does occur from the gastro- intestinal 
tract. 
In an attempt to localise the site of absorp- 
tion of the drug from the gastro -intestinal tract, the 
following experiments were arranged: - 
Ligation of the duodeno- pyloric junction: 
Group I Rats: 
a. Here, the animal was starved over night, and 
in the morning a median laparotomy incision 
was made under ether anaesthesia and the 
duodeno- pyloric junction secured and tied. 
b. Then a stomach tube was passed through the 
mouth - with the animal still under the 
anaesthesia - and tubocurarine injected 
through the tube into the stomach. 
c. The abdominal incision was then quickly 
stitched up, and the animal allowed to reco- 
ver from the anaesthesia. 
It was noticed then that the presence of 
large amounts of the drug (50- 100- 120mg. per kg. body 
!weight) introduced into the stomach in this way, was 
without any obvious effects on the animal for a period 
of two hours, after which the animal was painlessly 
killed. 
-52- 
killed. (After such an operation, animals were not 
allowed to live more than two hours: condition atta- 
ched to grant of Cert.B). Two animals were put on 
each of the lower doses and four on the higher dose. 
The weight of these rats ranged between 200 -260g. 
The observation that the presence of large amounts of 
the drug in the stomach, was without any visible 
effects would be due to the fact that the drug is 
either not absorbed from the stomach or that it is 
destroyed there. 
When the animal was killed, two hours after 
the operation, and the stomach contents examined, 
practically all the amount introduced was recovered 
from there. The drug was not absorbed by the gastric 
mucosa. 
Group II Rats: 
a. The animal here was also starved over night, 
and in the morning a median abdominal incis- 
ion made under ether anaesthesia and the 
duodeno- pyloric junction secured. 
b. Then a stomach tube was passed through the 
mouth, and manipulated from the abdominal 
wound into the duodenum. 
The tube was then kept in position by a 
loo se/ 
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loose loop placed around the duodeno- pyloric 
junction. 
c. The drug was then introduced into the small 
intestine by injecting it through the stomach 
tube. Then the latter was carefully with- 
drawn while the loose loop was tightened 
around the duodeno- pyloric junction. 
d. The laparotomy incision was then quickly 
stitched up and the animal allowed to recover 
from the anaesthesia. 
The injection of the drug by a needle dir- 
ectly into the stomach or intestinal lumen - 
through the abdominal wound - was avoided 
lest the drug got absorbed through the punc- 
ture caused by the needle. 
On recovery from the anaesthesia these rats 
were observed to pass quickly into a typical condition 
of curare paralysis of variable severity. In six 
rats, weighing between 200 -250g. when the dose of 
tubocurarine left inside the intestine was over 3mg./ 
kg. body weight,(i.e., 3.5mg. /kg. in four rats and 
4mg. /kg. in two rats), this curare paralysis was very 
severe, and progressed to complete respiratory arrest, 




Doses of tubocurarine (2- 2.5- 3mg.per kg.body 
weight), produced invariably the following picture: 
1. A certain degree of curare paralysis of variable 
severity starting about 4 -6 minutes after the 
internal administration. 
2. This paralysis extended over a period of 15 -25 
minutes, after which the animal recovered. It 
was severer when the dose left inside the intest- 
ine was 3mg.per kg. 
Four rats, weighing between 200- 260g., were 
used for each dose level. The results of these expe- 
riments are summarised in Table X. 
TABLE X 
The site of absorption of tubocurarine introduced 
into the gastro -intestinal tract of rats. 
Introduced proximal to 
duodeno- pyloric ligature. 
Introduced distal to duo - 
deno- pyloric ligature. 
Dose No. of Dose 
mg. /kg. rats Effects mg. /kg. 
50 2 None seen 2 
100 2 in 2hours 2.5 
3 








4 in 4 -6min 
4 Severe pa 
2 alysis an 
death. 
-55- 
It became obvious, therefore, that tubocurar- 
ine was absorbed from the mucous membrane of the small 
intestine, and that by this method of introduction,the 
size of the effective dose by mouth was reduced more 
than tenfold. 
It was also noticed that the duration of 
action of the drug was rather short, although the abs- 
orption started fairly soon. That renal excretion 
could be keeping pace with that rate did not seem very 
probable as it has been shown to be a relatively slow 
process. 
This suggested that this process of intestinal 
absorption may be one of "limited absorption ", limit- 
ation being probably due to another process taking 
place inside the intestine, thereby preventing any 
further absorption. 
It was suspected that the pancreatic juice 
might be causing inactivation of the drug. To invest- 
igate this, the following procedure was followed: 
The pancreatic juice of a cat was incubated with 
tubocurarine, at 37 °C. and the curariform activity of 
the mixgure evaluated at the end of two hours. 
Collection of /Pancreatic juice: 
The juice was collected from a 2kg. decerebr- 
ate cat, by a cannula introduced into the pancreatic 
duct/ 
-56- 
duct. The flow of the juice was stimulated by the 
injection of Isecretini prepared from the catt own 
small intestine by the method recommended by Sherring- 
I 
ton.(107). The juice was then divided into two port- 
ions "A" and t1B" of 0.3c.c. each. After inactivating 
"B's by heating it to about 90 °C. 0.lc.c. tubocurarine 
solution containing 10µg. was added to each portion 
and both portions then incubated at 37 °C. for two 
hours. 
No loss of the tubocurarine content of either 
mixture, could be detected. The pancreatic juice 
thus does not appear to catalyse the destruction of 
tubocurarine. 
In this connection it may be mentioned that 
Clement and Pistorio, in 1928, showed that bile and 
bile salts could precipitate the alkaloid from curare. 
(28) . 
So it is possible that when the drug reaches 
the small intestine, and while it is being absorbed, 
sane of it may be thrown out of action by a process of 
precipitation, and then destroyed along its course in 
the intestines. 
-57- 
The effect of water diuresis on the 
urinary excretion of tubocurarine in the rat. 
In these experiments the tubocurarine- equiv- 
alent in the urine of a group of rats was determined 
following the intramuscular administration of 0.3mg. 
tubocurarine per kg. body weight. 
These rats were starved over night and on 
the following day, they were injected with the same 
dose of the drug, just after they had received 50 c.c. 
water per kg. body weight by a stomach tube, and the 
curarine equivalent of their urine again determined. 
Three groups of rats, A. B. and C. each con- 
taining three male rats of body weights ranging bet- 
ween 230g. and 260g. were used. The total weight of 
group 4. was: 745g.; of B: 750g. and of C: 730g. 
In all cases, urine specimens were collected 
at the end of the fifth hour and the ninth hour 
following the injection. All specimens were 
extra- 
cted and examined in the usual way. 
The second samples (6th -9th hour), 
as well 
as the control preinjection samples, 
were devoid of 
curariform activity. 




showed curariform activity; and when the total tubocur- 
arine- equivalent of the urine was calculated, in each 
case, before and fater the water diuresis, an increase 
in the total equivalent was noticed to have followed 
upon the water -diuresis produced. 
The results are shown in Table XI. 
The effects of removal of both kidneys on curarized 
rats: 
In these experiments, the effects of double 
total nephrectomy on the degree of paralysis and dura- 
tion of action of tubocurarine was examined. 
The extent of the degree of paralysis in an 
intact animal is not easy to determine. However, 
since the way of spreading of the curare paralysis is 
such that the respiratory muscles are the last to be 
involved, and when the respiration is sufficiently 
affected, the animal is usually thrown into anoxaemic 
convulsions; the occurrence of convulsions among the 
various rats was taken as a crude measure of the extent 




The urinary excretion of tubocurarine 
(0.3mg. /kg.) given intramuscularly to rats, with and 

















After 50c.c. water /kg.. body weight bz stomach tube: 
Group A. 12.5m1. 68.2µg. 30.6 
Group B. 15ml. 6311g. 28 
31 Group C. 18ml. 67.8µg. 
From 
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From the course of spreading of this paraly- 
sis, the inability of the animal to lift up his head 
in response to a stimulus, i.e., head -drop (H.D. ), 
was taken as the starting point of the paralysis. 
AX1d as recovery from the paralysis occurs in 
the opposite way, the ability of the animal to lift upi 
his head in response to the same stimulus, i.e., head - 
lift (H. L.) was taken as the finishing point of this 
paralysis. 
The time elapsing between the occurrence of 
head -drop and head -lift being taken to represent 
roughly the duration of paralysis, and give some idea 
about the duration of action of the drug. 
To minimise the individual variation of the 
various animals in their reaction to tubocurarine, 
each animal in the group served as its own control. 
The period of time elapsing between the first control 
and the second experiment was not less than twenty - 
four hours. 
Thus the animal was injected on one day and 
its paralysis time determined, and on the next day both 
its kidneys removed. Three to four hours after the 
surgical interference, when the animal had recovered 




In a group of five rats, ranging in weight 
between 200g. -250g. these injections were made intra- 
venously in a dose of 0.08mg. per kg. body weight. 
One member of the group showed convulsions when it was 
injected after recovery from the operation. The 
average paralysis time for the group was increased 
from 12 minutes to 15.5 minutes. These results are 
shown in Tabe XII. 
TABLE XII 
Effects of double nephrectomy on the rats' 











































In another group of ten rats, weighing betweel 
200g. -280g. tubocurarine was injected intramuscularly 
in a dose of 0.3mg. /kg. body weight. Thirty per cent' 
of the animals convulsed when injected after recovery 
from/ 
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from the operation as compared with ten per cent con- 
vulsing when injected before the operation. 
The increase in the duration of action of the 
drug became more obvious,(from an average of 29.5min. 
to 40min.). These results are shown in Table XIII. 
TABLE XIII 
Effect of double nephrectomy on the rats' 
reaction to tubocurarine given intramuscularly.(0.3mg/ 
kg.). 
Exp.Duration 














1 32 - 44 + 
2 29 - 40 - 
3 26 - 34 - 
4 35 - 47 + 
5 24 + 39 - 
6 35 - 44 - 
7 26 - 35 - 
8 29 - 39 - 
9 31 - 38 + 
10 28 - 40 - 
It/ 
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It was also observed that although the dura- 
tion of action of the drug was increased in the doubly 
nephrectomized series, the recovery of the animals, 
from. the tubocurarine paralysis, by the end of this 
period was apparently complete. 
Thus, although the kidneys seem to be an imp - 
portant organ in the elimination of the drug, renal 
damage - in these cases amounting to total nephrectomy- 
does not prevent the full recovery of the animal. 
Effects of hepatectomy on curarized rats: 
In a group of five rats,(weighing between 
200g.- 250g.) also acting as their own controls, the 
reactions of each rat to tubocurarine was determined 
before and after the removal of about 75% of the liver, 
While the duration of paralysis in the control period 
was: 32,35,32, 29 and 36 min.; after the subtotal 
hepatectomy, it became: 32,38,34, 30 and 35 min. res- 
pectively. No convulsions were observed to occur in 
either case and there was no appreciable difference 
between the average duration of paralysis following 
the injection, before and after hepatectomy. 
All injections were made intramuscularly in 
a dose of 0.3mg. /kg. body weight. 
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Experiments on mice. 
A, balance sheet for tubocurarine. 
The balance sheet for tubocurarine was cons- 
tructed from experiments on mice, in which the drug 
was injected intravenously in a dose of 0.2mg. /kg. 
Male animals weighing between 20g. -25g. were used and 
the excreta were collected at variable intervals 
following the injection. 
The animals were killed, minced and the tubo- 
curarine equivalent of the extracts of the mince and 
of the excreta determined. This was done at: 0, 1 
and 4 hours following the injection. In the first 




Balance sheet, showing recovery of tubocur- 









Mean percent - 
age recovery. 
hours (g.) mouse 
(mg.) mice excreta mice excret 
20 
20 .004 92 - 
0 92.5 - 
22 
22 .0044 93 - 
20 
20 .004 76 - 
1 78 - 
25 
25 .005 80 - 
22 
22 .0044 20 30 
4 15 26 
25 
_ 
25 .005 10 22 
Table XIV, shows the relationship between the 
amounts in the mice and in the excreta, and the per- 
centage recovery of the dose. These results show 
that during the first four hours 26% of the dose was 
excreted/ 
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excreted, and 59% of the dose disappeared in some 




FOLLOWING RAPID INTRAVENOUS INJECTION 
OF TUBOCURARINE IN THE GUINEA -PIG. 
During the course of this work, it was noted 
that sometimes a rapid intravenous injection of tubo- 
curarm a produced effects not produced by slower inj- 
ections. In the conscious subject, Exp.II, the 
sudden severe respiratory embarrassment which occurred 
during the early part of the experiment had followed 
upon such an injection, and was believed to be prob- 
ably due to a condition of bronchoconstriction. 
The occurrence of bronchospasm was reported 
in 1936, by West, to follow the injection of curarme 
in some cases of Parkinsonian rigidity.(119). It was 
believed that this effect was due to the presence of 
an impurity contaminating the sample used.(120). 
Numerous clinical reports, however, continued 
to mention the occurrence of an undesirable and dan- 
gerous side reaction with a sudden onset, following 
upon the administration of curare- preparations to 
patients. 
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patients.(36,60, 62,121). The reaction was described 
as respiratory difficulty accompanied by cyanosis. 
Increased resistance to inflation of the lungs by man- 
ual compression on the breathing bag has been reported 
by Whitacre and Fisher (121), and by Holaday(62), to 
occur in some anaesthetized patients given into- 
costrin. This respiratory spasm was observed by the 
same workers to be relieved by another injection of 
the drug. 
In reports on animal experimentation, a re- 
action to curare administration, similar to that 
occurring in man has been described. Cole(32), rep- 
orted the occurrence of cyanosis in dogs following the 
administration of intocostrin, despite vigorous arti- 
ficial respiration through an endotracheal tube, and 
he attributed this condition to bronchospasm. 
Since Alam, Anrep, Barsoum, Talaat and Wein- 
inger, in 1939, demonstrated the release of histamine 
as a result of curarine injection (1), evidence has 
been accumulating of the occurrence of histamine re- 
actions following injection of even the most purified 
preparations, intocostrin and tubocurarine. 
Comroe and Dripps, in 1946, showed that cert- 
ain/ 
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certain vascular effects of intocostrin in man, i.e., 
the wheal and flare response, were similar to hista- 
mine reactions.(33). 
Grob, Harvey and Lilienthal, in 1947, report- 
ed similar reactions to occur with dextro -tubocurarine 
chloride. (56) . 
Feldberg and Holmes, reported that the inj- 
ection of curarine caused - like that of histamine - 
gastric secretion of free HCl.(42). 
Landmesser has recently shown that broncho- 
constriction occurred in spinal dogs as a result of 
the injection of curarizing doses of the pure alkaloi- 
dal salt d- tubocurarine chloride and that that was due 
to the histamine liberated.(8l). He used the Drinker - 
Murphy infant resuscitator adapted to record bronchial 
calibre by the plethysmographic method of Jackson. 
Since probably the absolute contra- indication 
to the clinical use of tubocurarine may be the inabil- 
ity to perform artificial respiration and since such 
a position might develop if bronchoconstriction occurs 
even if the means of artificial respiration were at 
hand, its occurrence should be avoided. 
Experimental 
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E Tp er l? en ,, a' roce daL e . 
In the experiments to be described, the 
bronche- constrictor poser of tuboc narine is ' ons- 
trated. As it was proba le that this effect is due 
to the histamine mobilised as a result of the 
ion, the modification of such an effect by an an-`_- 
h; ,stami.ne - notable for its efficiency in 
histamine bronchospasmm - namely, nsoantergam, was 
observed. 
ea -pigs were chosen for these experiments 
as they have been shown to be most susce tible to t 
action of tubocurarine (41). 
Furthermore, if the bronchoeoostric Lor prop- 
erties of tu'cacurarire are due to the 11' eration of 
histamine, the effects of this substance may be more 
easily reflected on the guinea -pig bronchi. 
Decerebr.ate animals of both sexes, weighing 
5OOg. -650g. were used. The animal was anaesthetized 
with ethyl ether aid a tracheal glass cannula - with 
a side tube attached - introduced into the trachea, 
an d the anaesthesia continued through a l'tolff c s bottle, 
until the brain was destroyed. 
Then respiration was installed by 
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a pump, delivering air at a constant pressure. The 
chest cavity was opened by severing the junction bet- 
ween the xyphoid process and the body of the sternum, 
then cutting the latter upwards in the middle line for 
about 2 -2.5 inches from its lower margin. 
The two edges of the chest wall were fixed 
moderately apart by rigid clamps. The opening thus 
made in the chest was well covered by warm, moist 
gauze. 
The side tube in the tracheal cannula was 
then connected - through a piece of pressure tubing - 
to a recording tambour, moving a lever which amplified 
its movements about twenty times and recorded them on 
a smoked drum. 
4 sensitive tambour of about 4 inches dia- 
meter covered with thin rubber at a suitable initial 
tension was used. (46) . 
The air delivered by the pump will be distri- 
buted between the bronchi and the tambour, and 
state of balance recorded by the lever on the drum. 
The occurrence of constriction in the bronchial cali- 
bre will result in accommodation of less air in the 
bronchi, thus more air will be deflected along the aide 
tube to the tambour, causing an increase in the ampli- 
tude of the record. 
Better 
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Better records were obtained with the chest 
opened than when it was closed. 
The drugs were injected intravenously through 
a cannula connected to a superficial neck vein. Tubo- 
curarine was used in curarizing doses of 0.03mg. in 
lc.c. saline per kg. body weight; histamine as 0.01mg. 
of the base in lc.c. saline per kg. body weight; un- 
less otherwise indicated. 
For protection with neoantergan, this was 
made by giving the drug in doses of ling. per kg. body 
weight subcutaneously 0.5-1 hour before the operation, 
and for the treatment of an attack it was given as 
0.1- 0.2mg. per kg. in lc.c. saline intravenously. All 
intravenous injections were given rapidly (i.e. in 
2 -3 sec.) unless otherwise mentioned. 
The slow intravenous injection of tubocurar- 
ine was made after passing a capillary glass tube into 
the drug solution filled into a burette connected to 
the vein cannula. The drug was infused at the rate 
at which the air bubbles were leaving the lower end 
of the capillary tube, and this was adjusted so that 
the corresponding dose would flow over a period of 
one minute or slightly more. 
With the above arrangement of experiments 
the following results were obtained: 
Results/ 
FIGURE VII 
T.R. Tubocurarine injected rapidly (151/g); 
7.R1. same dose similarly injected 6 mins. 
later; H= Histamine (511g): G.Pig =500g. 
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RESULTS 
Bronchoconstriction caused by tubocurarine: 
The intravenous injection of tubocurarine in 
the unprotected animal caused the development of a 
condition of bronchoconstriction reaching its maximum 
in about half a minute and passing off gradually in 
about four minutes. 
When the constriction was apparently relieved, 
a second dose of the drug, similarly injected about 
six minutes after the first, was without any effect. 
The subsequent injection of histamine, however, pro - 
duced a bronchospasm reaching its maximum also in 
about half a minute, but it stayed longer and was more 
sustained. 
Fig.VII, is an example of such effects pro - 
duced in a guinea -pig weighing 500g. Larger initial 
(doses of tubocurarine did not appreciably increase they 
degree of constriction. 
This refractoriness of the animal to a secon 
dose of tubocurarine - when the effects of the first 
dose have passed off - was still there, when this 
second dose was greater than the first one 
and given 
after a longer interval. Therefore, no animal could 
be used more than once to show these responses. 
Fig.VIII /, 
1 TR., t N. 
MIN 
FIGURE VIII 
T.R. Tubocurarine injected rapidly (16.5µg); 
T.R1: 
Tubocurarine (66µg) injected rapidly 90 
min. later. 
H= Histamine (5.5µg) G.Pig=550g. 
FIGURE IX 
N.P._ normal record of an animal protected with neoant- 
ergan (1mg. /kg.) subcutaneously 1 hour previously. 
T.R. =tubocurarine injected rapidly (6011g.). 
H=Histanine (5011g). G.Pig 520g. 
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Fig.VIII, is an example of such an experiment 
where a second dose four times larger than the first 
and rapidly injected ninety minutes after the first 
dose was without any effect. This, however, was 
followed by the usual histamine responses. Of eight- 
een guinea -pigs however, seven were refractory to the 
first rapid dose of tubocurarine but not to histamine. 
Th prevention_ of bronchoconstriction caused by tubo- 
curarine 
a. By protection with neoantergan: 
In these experiments, done on seven guinea 
pigs, the animal was protected 5-1 hour before the op- 
eration by the subcutaneous injection of neoantergan 
lmg. /kg. body weight. 
In these cases, the rapid injection of tubo- 
curarine did not precipitate an attack of bronchocons- 
triction. 
The efficiency of such a protection is illus- 
trated in Fig.IX. 
In this case, tubocurarine was rapidly inject- 
ed (about four times the usual dose in a 520g. guinea - 
pig), fully sixty minutes after the animal had received 
its subcutaneous protection. No constriction result- 






TR., ? H. 
{MIN 
FIGURE X 
N= normal; T.S. =tubocurarine (22511g) injected slowly 
at a rate of 15µg. /min. T.R. =tubocurarine (14.g) in- 
jected rapidly. T.R1 =same dose similarly injected 
7min. later. 
H =Histamine (5µg) . G.Pig 500g. 
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half an hour later, this showed a very slight trans- 
ient effect. 
b. By slow intravenous infusion: 
When the dose of tubocurarine was injected 
slowly, over a period of one minute or more, this pro- 
cedure in itself seemed to have modified the reaction 
of the animal to tubocurarine. No bronchoconstrictor 
effects were noticed to follow upon such an admini- 
stration, in seven guinea-pigs.When the slow intrav- 
enous infusion was stopped and a dose of the drug 
injected rapidly, the usual bronchoconstrictor effects 
were produced. Then when a second rapid injection of 
the drug was given, after the effects of the first 
dose had passed off, the animal showed again the usual 
refractoriness; but was not refractory to the inject- 
ion of histamine that followed. 
Fig.X, is an example of such experiments, 
where the slow infusion of 225µg. tubocurarine over a 
period of fifteen minutes, at a rate of 15µg. /min. in 
¡a 500g. guinea -pig, did not produce any bronchial 
spasm. 
When the infusion was over, the injection of 
15µg. in the usual rapid way produced bronchconstrict - 




T.S. =tubocurarine (150µg) infused slowly over a period 
of 10min; T.R.= tubocurarine (1511g) injected rapidly; 
NG= neoantergan 0.1mg; H= Histamine (7011g), given 1 hr. 
after T.R. G.Pig=500g. 
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dose of 15µg. tubocurarine was injected rapidly about 
seven minutes later. 
The injection however, of 5µg. histamine 
after that produced a definite spasm. 
Treatment of bronchoconstriction caused by tubo- 
curarine: 
In these experiments, it was decided not to 
give any degree of protection to the animals before- 
hand, but to develop in them an attack of tubocurarine 
bronchoconstriction and then see how far such an 
attack could be modified, by the administration of neo 
antergan, at various stages of its development. 
Fig.XI, shows the production of such an 
attack in a 500g. guinea -pig by the rapid intravenous 
administration of 15µg. tubocurarine. 
When the attack was at its peak, the rapid 
injection of neoantergan (0.1mg. intravenously) appar -1 
ently relieved this attack and restored the bronchial 
calibre, to some degree. 
.bout one hour later, the effects of the 
antihistamine seemed to have weakened, and when a 
large dose of histamine (70µg.) was given, this caused 
a bronchoconstriction which was again effectively 
treated at its peak by intravenous neoantergan. 
The/ 
FIGURE XII 
T.R.= tubocurarine (18µg) injected rapidly; NG= neoantr 
ergan 0.12mg; T.Rz= tubocurarine (36µg) injected rap 
idly. H= Histamine (10µg) given half an hour after 
T.R. G.Pig=600g. 
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The first part of this curve shows the harm- 
lessness of the slow injection of tubocurarine on the 
bronchi, where 15011g. were infused slowly at a rate 
of 15µg. /min. 
\hen an attack was left to pass its peak and 
get fully developed the neoantergan treatment seemed 
to relieve it, to some degree. 
Fig.XII, is an example of such a condition 
where the bronchoconstrictor attack in a 600g. guinea - 
pig, was left to become fully developed in about one 
minute, when the intravenous injection of 0.12mg. 
neoantergan accelerated recovery. After five minutes, 
a second larger dose of tubocurarine, 3611g. rapidly 
injected, did not produce any effect, nor did. 1011g. 
histamine injected half an hour later. 
If an attack is dealt with early enough by 
the prompt administration of neoantergan, its full 
development is apparently suppressed. 
Fig.XIII, shows such an effect, where in a 
600g. guinea -pig, when an attack was starting to dev- 
elop as a result of a rapid intravenous injection of 
1811g. tubocurarine, it was possible to abort it prem- 
aturely by the prompt intravenous administration of 
.06mg. neoantergan. The animal was completely refra- 




T.R. =tubocurarine (18µg) injected rapidly; NG =neoant 
ergan 0.06mg; T.R1 =tubocurarine (3611g) injected rap -1 
idly 1 hour later. G.Pig =6008. 
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ly injected one hour later. 
It appears therefore, that the rapid intra- 
venous injection of tubocurarine in the guinea-pig, 
under these conditions, produced a state of broncho- 
constriction. The animal later became refractory to 
a second dose of tubocurarine but not to histamine. 
A condition thus produced could be conveni- 
ently treated by the prompt administration of intra- 
venous neoantergan given at the peak of the attack or 
when it was fully developed. If this treatment was 
carried out early enough - just at the beginning of 
the spasm - the attack could seemingly be aborted 
and its further development checked. 
Neoantergan, given subcutaneouslyO.5 -1 hour 
before a rapid injection of tubocurarine has apparent- 
ly prevented such an attack. If such a protection 
was not provided, but the drug injected slowly intra- 
venously no such attack developed. 
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THE INH&I.[.TION OF TUBOCUR NINE 
In these experiments, guinea -pigs were 
exposed to an aerosol of aqueous solution of tubocu- 
rarine, with and without preliminary protection by 
neoantergan. The inhalation was meant to obviate, 
at least during the early part of the experiment, the 
general action of the drug, in order to get the effect 
of its direct application upon the bronchial system of 
the living animal. 
Method: 
A Collison spray atomiser was used after con- 
necting it to an animal glass -chamber, and modifying 
its container so that it was possible to economise in 
the use of the drug. The glass bottle container was 
filled to threequarters of its capacity, with a mould 
of plaster of Paris, "P "(Fig.XIV), in the middle of 
which a hole was drilled to hold about 25- 30c.c. of 
water. This hole acts as the new container of the 
apparatus through which the central spraying piston, 
"S" passes to a short distance from its bottom. 
The 
sides and edges of the hole were made sloping 
and they, 




DIAGRAM OF A MODIFIED COLLISON SPRAY ATOMISER . 
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coated with a water -proof layer of varnish. 
The inner sides of the remaining part of the 
glass bottle were covered with a thin layer of wax, 
to prevent water particles from forming large drops 
on the glass during spraying. These particles will 
instead, fall on the upper sloping surface of the 
plaster mould and run down into the hole from whence 
they will be resprayed. 
The cloud was produced by passing a continu- 
ous stream of compressed air into the aqueous solut- 
ion in the container. The air was delivered from a 
compressed air cylinder, "C ", at a pressure of 201bs. 
per square inch, and maintained constant by an adjust- 
ing screw. The cloud was then taken by a curved 
glass tube to just below the centre of a wire mesh 
platform fitted horizontally inside a large glass 
desiccator which acted as an animal chamber. The 
upper part of the desiccator was divided by a verti- 
cal wire mesh screen into two compartments of equal 
size, "Q,r' and "B ", each holding one animal. The 
cloud escaped by a tube "D" fitted into 
a hole, drill- 
ed in the centre of the desiccator dome. 
The output of the atomiser 
was about ten 




Tubocurarine was used as 3% watery solution. Two 
guinea -pigs of the same sex and weight were used at a 
time, one in each compartment of the animal chamber. 
One of the animals usually received a subcutaneous 
injection of lmg. /kg. body weight neoantergan,C''.5 -1 
hour before starting the spray. Ten such pairs of 
animals were used in these experiments. The duration 
of spray was 15 -20 minutes. 
Results: 
No signs of bronchoconstriction were observed 
in any of the animals. It made no difference to the 
animal whether had or had not been protected before 
hand with neoantergan. 
tit the end of the period of spray both anim- 
als, when taken out, exhibited some signs of the gen- 
eral action of the drug in the form of a moderate deg- 
ree of paralysis from which they recovered in about 
seven to ten minutes. 
When these animals were exposed, the follow- 
ing day, to an aerosol of an aqueous solution 
of 2% 
histamine base - after giving a fresh protective 
inj- 
ection to the control - the unprotected animal 
showed 
the usual signs of severe histamine 
bronchospasm, 




In the control animal protection was complete 
It may be concluded that these results are in 
support of the evidence that the bronchoconstrictor 
power of tubocurarine is probably not due to the drug 
itself, but to its histamine releasing properties. 
It is, further, probable that tubocurarine 
may not be able to release histamine from the lungs. 
This may also be compatible with the observ- 
ation of Alam et al (1), that the lungs are not parti- 
cipating in the histamine mobilisation following upon 
the injection of the drug. 
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DISCU,SSION 
The various stages of tubocurarine paralysis 
could be correlated with the concentrations of the 
drug in the plasma, though the concentrations at the 
neuro- muscular junction must be more intimately re- 
lated to these effects. The degree of this paralysis 
seems to depend on the sensitivity of the individual 
to tubocurarine. Gray and Halton, in 1948, reported 
the development of severe paralytic reactions, 
ing to complete respiratory arrest, to follow upon the 
injection of a small dose (2mg.) of tubocurarine in a 
adult non -myasthenic patient.(54). As the use of 
ordinary dose of tubocurarine may prove hazardous in 
myasthenic patient, (7,31), the use of a preliminary 
small dose, to test the reaction of an individual may 
be worth trying to obviate unpleasant consequences in 
an otherwise idiosyncrotic individual. 
In the conscious human subject (Exp.II), 
tub- 
ocurarine was detected in his saliva, in a concentra- 
tion of 1.211g. /ml. occurring twenty -one 
minutes after 
the injection. The drug was not concentrated 
by the 
salivary glands, as the plasma level 
at this time was 
about 211g. /m1. 
About 12% of the dose injected 
was present in 
his fasting gastric juice, forty 
-three minutes after. 
the/ 
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the intravenous injection. The excretion of curar- 
ine along these channels was reported by Koch, in 
1870, and von Huber drew attention to this fact in 
1922(76). In this respect, tubocurarine is behaving 
in a similar way to some heavy metals, and alkaloids, 
e.g., morphine. 
The presence in the C.S.F. of this subject 
of curariform activity equivalent to 2.5µg. tubocur- 
arine per ml. may be of some clinical interest. It 
occurred at a time when the concentration of the drug 
in the plasma was about lµg. per ml. Everett has 
shown that when the drug is brought into direct con- 
tact with the central nervous system in a sufficient 
concentration (o.lmg. /kg. intracysternally in the 
rabbit), it is liable to set up convulsions of cen- 
tral origin, and he warned against the use of tubocu- 
rarine in cases of suspected pathological changes in 
the blood vessels of the C.N. S (41) . The occurrence 
of violent convulsions following the intravenous 
admi- 
nistration of tubocurarine in a case of schizophrenia 
was reported by Morrison so in 1948(91). 
This may be 
due to a greater leakage of the drug from 
the vessels 
of a central nervous system set 
at fault, and 
Everett 
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Evere tt } s warning may justifiably be emphasised. 
Tillie, in 1890, was among the early workers 
who clearly demonstrated that the direct application 
of curarine to the C.N.S. induced prompt convulsions. 
(113). Similar results were obtained in the frog and 
in maimnals by other workers, (86,103) . There is at 
present, however, a controversy about the action of 
the drug on the spontaneous resting potentials, of 
which the electroencephalograph is an indicator. 
McIntyre noticed that tubocurarine causes increased 
electroencephalographic activity in dogs followed by 
Idepression.(87); while Smith, Brown, Toman and Goodman 
(109); and Girden, (50 ), did not observe such changes 
to occur in mammals. 
No apparent changes in the sensations or 
any 
detectable anaesthetic effects were observed in the 
experiments described in this work, to follow 
the 
injection of tubocurarine in man. This 
was also 
observed by Prescott, Organe and Rowbotham,(97); 
and 
by ,Smith et al (109); although it has 
been reported 
by Whitacre and Fisher that intocostrin 
could produce 
general anaesthesia.(121). 
It has been known that 
the kidneys play an 
important part in the elimination 
of the drug. The 
urinary/ 
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urinary excretion of crude curare was demonstrated by 
Voisin and Lionville (114), who poisoned rabbits in 
series by taking the urine of the first and injecting 
it into a second rabbit. Similar experiments were 
conducted by Bidder, who was likewise able to poison 
frogs in succession (13). Boehm was able to demon- 
strate the presence of the drug in the urine of cur - 
arized animals by the development of a purple ring at 
the zone of its contact with concentrated sulphuric 
acid.(16). 
Claude Bernard also showed that obstruction 
to the urine outflow increased the rate of poisoning 
in the rabbit,(12). 
Here, however, it has been found that the 
renal excretion of tubocurarine following an intra- 
venous injection is a relatively slow process. In 
hourly samples taken from man it was possible to de- 
tect it three hours and sometimes four hours, 
after 
such an administration. The greater part of 
the 
texcretion, however, occurred during the 
first hour. 
In the rabbit, as early as ten minutes 
after the intra- 
venous administration of the drug, 
the apparent tubo- 
curarine content of the kidneys per 
g. tissue weight 




the drug seemed to be uniformly distributed. 
The beneficial effect of water- diuresis in 
the elimination of the drug by the kidneys was illus- 
trated in the rat, in which the total excretion of the 
drug following its intramuscular administration was 
increased under water diuresis. The ancient use, by 
the Indians, of large amounts of water by mouth as an 
antidote to arrow -poisoning, may be of interest 1(87) . 
Although the kidneys appeared to be playing 
an important part in the elimination of the drug, yet 
the relief from the obvious effects of curarization 
did not seem to depend entirely upon renal excretion. 
This was illustrated by a series of experiments on 
doubly nephrectomized rats. In these animals, al- 
though the total removal of both kidneys caused a 
slight increase in the duration of action of the drug, 
yet the recovery of the animals by the end of 
this 
period was apparently complete. 
From the results of the hepatectomy 
experi- 
ments, it did not seem likely that 
the liver was pro- 
viding an appreciable degree of protection 
against 
the drug effects. It was also concluded 
by Rothber- 
ger and Winterberg,1905, (102 ); and 
later by Polimanti 
in 1914(96), that the liver plays 
no part in detoxi- 
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detoxifying the drug. 
These findings may be in agreement with recent 
clinical observations by Wall in 1947,(115), that 
renal or hepatic damage does not necessarily constit- 
ute a serious contraindication to the clinical use of 
the drug. There must be some other mechanism by 
which tubocurarine disappears from the body. The 
experiments on mice show that the drug is actually in- 
activated in the body, since 60% of the dose injected 
disappeared in four hours. The site of this inacti- 
vation is unknown. It may perhaps occur in voluntary 
muscle, which was found to contain 40% of the dose in 
the experiments on rabbits. 
Gros,(57) obtained evidence that the absorp- 
tion from mucous surfaces is poor, but absorption from 
serous cavities is fairly rapid. Bernard showed 
that 
the drug given by mouth was not destroyed by the 
gastric juice, as he was able to poison frogs 
by the 
injection of the stomach contents of dogs 
previously 
given curare by mouth.(11). It is 
almost a popular 
belief that the drug is ineffective 
when given by 
mouth, either because it is not 
absorbed from the 
gastro intestinal tract or because 
it is destroyed 
there or because it is excreted 
as quickly as it is 
absorbed, so that an effective 




However, from experiments conducted in this 
work, and as far as tubocurarine is concerned, it was 
noticed that in the rat, and within certain range of 
dosage (30- 40mg. /kg.), typical paralytic effects were 
produced, when the drug was given by stomach tube, 
indicating absorption. That absorption had taken 
place from the gastro -intestinal tract of these ani- 
mals was also shown by the presence in their urine of 
a part of the dose administered. 
In an attempt to localise the site of absorp- 
tion of the drug from the alimentary tract, the drug 
was introduced directly into the stomach or small 
intestine respectively after tying the duodeno- pyloric 
junction through an abdominal incision. In this case 
the presence of large amounts of the drug in the sto- 
mach, over 100mg. /kg. body weight, was without any 
obvious effects on the animal. That was probably 
due to lack of effective absorption from this organ. 
But, when the drug was introduced 
directly 
into the small intestine, in a much smaller 
dose 
(2- 3mg. /kg.), signs of absorption developed 
rather 
rapidly, in about 4 -6 minutes, and progressed 
fatally 
with an increase of this dose. 
It/ 
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It is possible that with such drugs, pro- 
ducing obvious characteristic signs within a short 
interval after administration, the widely different 
absorbing properties of these neighbouring mucous 
membranes could be demonstrated pharmacologically. 
This may be another instance of the use of tubocur- 
arine as a pharmacological tool. 
The effects of the drug (2- 3mg. /kg.) thus 
absorbed were, however, of short duration, since in 
15 -25 minutes, the animal seemed to have recovered 
from the obvious drug effects. It seemed unlikely 
that the relatively slow renal excretion could be 
keeping pace with such a rapid absorption, to an ext- 
ent which would prevent the development of a danger- 
ous blood level. 
It is possible that the continuation of abs- 
orption from the small intestine was limited by 
a pr 
cess of precipitation and that the drug may be furthe' 
destroyed along its course in the intestine. Clement 
and Pistorio showed in 1928, that bile 
and bile salts 
could precipitate the alkaloid from crude 
curare.(28). 
The pancreatic juice was 
shown to be not tak 
ing part in the destruction of the 
drug. 
It was also noticed that 
this method of 
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administration of the drug directly into the intestine 
has reduced the size of the effective dose by mouth 
more than tenfold. 
It was proposed - at sometime during this 
work - to imitate this clinically, as by giving the 
drug in keratin coated capsules in the hope of getting 
desirable effects in spastic paralytic conditions. 
But probably the limited absorption of the drug from 
the intestine, and the short duration of action of 
the drug thus absorbed, may limit the clinical value 
of the drug administered that way. 
The sphere of usefulness of tubocurarine in 
clinical practice, however, is getting wider as the 
various conditions known to stand as contraindicat- 
ions to its application are being reconsidered. 
Curarizatïon is believed to occur with little or no 
manifestations of haemodynamic disturbances; and it 
is only when secondary effects are allowed to develop 
that the cardio vascular indices are subsequently dis- 
turbed. (109). 
Probably the vital system whose responses 
provide the most important contraindications to the 
use of tubocurarine is the respiratory system. There- 
fore one must be definitely convinced before 
admini- 




respiratory depression that might ensue. Artificial 
respiration applied by the Schaefer or similar methods 
may completely fail to resuscitate and thus means of 
artificial respiration under positive pressure should 
always be available(87). This latter method, however, 
may prove inadequate if the bronchial calibre is seri- 
ously interfered with. 
It appears that a certain degree of such 
interference may be caused,in the form of broncho- 
constriction, by the use of the drug itself. 
This was observed many years ago by West, 
using the crude drug (119); but recently similar 
reports followed describing such a condition to occur 
after the use of the most purified preparations.(32, 
81). 
When Alam et al (1), demonstrated that hista- 
mine was released, from pre -existing stores in the 
tissues, after the intravenous injection of curarine 
and that the histamine thus released circulated in a 
physiologically active form, reports followed that 
such a release could occur following upon the admini- 
stration of intocostrin and tubocurarine.(33,56). 
This was mostly shown clinically to occur in the form 
of vascular reactions similar to those of histamine. 
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Clinically, it was also observed that occas- 
ionally some degree of bronchial spasm occurred, 
following the injection, as evidenced by increased 
resistance to pressure on the breathing bag.(36, 60, 
121). 
In the conscious human subject, Exp.II, 
described here, a similar condition had resulted whic 
is believed to be due to the same cause. 
Experimentally, Landmesser has clearly shown 
recently, that active bronchoconstriction occurred in 
spinal dogs as a result of the release of histamine 
following upon the injection of tubocurarine.(Sl). 
The exposure of the living guinea-pig to an 
aqueous tubocurarine aerosol, in experiments described 
here, was without obvious harmful effects on their 
bronchi. These animals showed at the end of the in- 
halation period, some degree of the general action of 
the drug. It is possible that tubocurarine applied . 
this way may not be causing bronchoconstriction by it- 
self nor able to release sufficient histamine to 
cause it. 
Similar results to those of Landmesser were 
obtained here using the spinal guinea -pig. That the 
bronchoconstriction produced in these animals as a 
result/ 
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result of the rapid intravenous injection of tubocu- 
rarine was probably due to the histamine liberated, 
may be seen from the fact that repetition of the 
injection - after the effects of the first dose had 
apparently disappeared - did not produce obvious eff- 
ects. The assumption_ is that the first injection ha 
probably depleted most of the histamine stores in the 
tissues. 
The clinical observation that in the event 
of such bronchoconstriction, a second injection of the 
drug seemed to relieve it, may be explained by the 
observation that the second injection was probably 
acting on exhausted histamine stores and might have 
thus been unable to produce bronchoconstriction, 
while the constrictor effects of the first dose were 
gradually passing off. 
Furthermore, premedication of the animals 
by an antihistamine, notable for its efficiency in 
counteracting histamine bronchospasm, namely, neo- 
antergan was effective in protecting the guinea -pigs 
against bronchospasm produced by the rapid intra- 
venous injection of tubocurarine. 
It was also possible to prevent the bronch- 
ial spasm in the guinea -pigs by injecting the curari- 
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curarizing dose of the drug slowly intravenously, over 
a period of one minute or more. In this way, it was 
possible to infuse ten to fifteen times this dose, 
without producing signs of bronchoconstriction. It 
may be that the histamine mobilising power of the drug 
was reduced by giving it that way, or that whatever 
small amounts of histamine were released at a time, 
were rapidly taken up by the tissues. 
However, it seemed that a histamine level 
sufficient to precipitate such an attack was not 
easily built up under such conditions. 
It may be remembered that in the event of 
bronchoconstriction, artificial respiration under pos- 
itive pressure - which may be the only reliable life- 
saving measure in curarization - may be rendered diff- 
icult. Such a condition will probably be aggravated 
by an additional reduction in the size of the chest 
cavity, resulting from weakness and loss of tone of 
the respiratory muscles with subsequent rise of the 
intrapleural pressure. All possible precautions 
should therefore be taken to obviate such conditions. 
Should respiratory depression ensue from the paralyti 
actions of the drug on the respiratory muscles, there 
will then be no difficulty in artificially inflating 
and deflating the lungs. 
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SUMMARY 
1. The method described by Jalon for estimating 
tubocurarine by its action on the frog's rectus 
abdominus, was adopted for determining the drug 
equivalent of tissue extracts and biological fluids. 
This method was used to follow the fate of the drug 
in man and animals. 
2. The immediate volume of distribution on intra- 
venous injection corresponds to the plasma volume. 
The drug does not enter the blood cells. It dis- 
appears from the plasma exporentially with a halving 
time of about thirteen minutes. These conclusions 
apply both to man and to rabbits. 
3. In the conscious human subject, a concentration 
of 4k.g. per ml. in the plasma causes complete par- 
alysis. A concentration of lµg. per ml. has very 
little effect. 
4. About 20 -40% of the drug appears in the urine. 
This percentage may be increased by water diuresis. 
Excretion continues for several hours, even when the 
paralysis only lasts about half an hour. 
5. The main route of disappearance of the drug frorl. 
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the body does not depend on the kidneys, since 
double nephrectomy in rats did no more than 
slightly delay full recovery from paralysis. 
By extracting whole mice, it was shown that 
about 60jó of the dose was inactivated in the body 
within four hours. 
Since subtotal hepatectomy in rats did not app- 
reciably affect the duration of paralysis, the 
liver is probably not the main site of inactiv- 
ation. It is possible that inactivation occurs 
in voluntary muscles, which were found to contain 
4070 of the dose in an experiment on rabbits. 
6. The effective dose by oral administration in 
rats is about 100 times the effective dose by 
intramuscular administration. Absorption occurs 
in the small intestine but not in the stomach. 
On intravenous injection, appreciable quantities 
(12/4 of the dose) may be excreted in the stomch. 
7. A rapid intravenous injection of tubocurarine 
usually causes bronchoconstriction in guinea -pigs. 
second injection has no such effect. 
The effect may be prevented or interrupted by 
neoantergan and is probably due to the release of 
histamine ./ 
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histamine. The best way to avoid this effect 
in the clinical use of tubocurarine is to give 
the injection slowly. Slow injections of large 
doses in guinea -pigs had no effect on the bronchi, 
although a dose ten to fifteen times smaller 
caused bronchoconstriction when given rapidly. 
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